Country-wide distribution of the nitrile female condom (FC2) in Brazil and South Africa: A cost-effectiveness analysis

AIDS

Volumn 20, Issue 16, 2006, Pages 2091-2098

  Dowdy, David W ^a   Sweat, Michael D ^a   Holtgrave, David R ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Economic evaluation; Female condom; HIV; Modeling; Prevention

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BRAZIL; CONDOM; CONTRACEPTIVE DEVICE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PREVALENCE; PRIORITY JOURNAL; RISK REDUCTION; SENSITIVITY ANALYSIS; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SOUTH AFRICA;

ADOLESCENT; ADULT; BRAZIL; CONDOMS, FEMALE; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; MIDDLE AGED; MODELS, ECONOMETRIC; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA;

EID: 33750244173     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000247567.57762.fb     Document Type: Article

References (40)

1. Pinkerton SD, Abramson PR. Effectiveness of condoms in preventing HIV transmission. Soc Sci Med 1997; 44:1303-1312.
2. Shelton JD, Johnston B. Condom gap in Africa: evidence from donor agencies and key informants. Br Med J 2001; 323:139.
3. MeasureDHS. HIV/AIDS Survey Indicators Database. Calverton, MD: MeasureDHS; 2005. http://www.measuredhs.com/hivdata/data/start.cfm.
4. Minnis AM, Padian NS. Effectiveness of female controlled barrier methods in preventing sexually transmitted infections and HIV: current evidence and future research directions. Sex Transm Infect 2005; 81:193-200.
5. Trussell J, Sturgen K, Strickler J, Dominik R. Comparative contraceptive efficacy of the female condom and other barrier methods. Fam Plann Perspect 1994; 26:66-72.
6. French PP, Latka M, Gollub EL, Rogers C, Hoover DR, Stein ZA. Use-effectiveness of the female versus male condom in preventing sexually transmitted disease in women. Sex Transm Dis 2003; 30:433-439.
7. Farr G, Gabelnick H, Sturgen K, Dorflinger L. Contraceptive efficacy and acceptability of the female condom. Am J Public Health 1994; 84:1960-1964.
8. Fontanet AL, Saba J, Chandelying V, Sakondhavat C, Bhiraleus P, Rugpao S, et al. Protection against sexually transmitted diseases by granting sex workers in Thailand the choice of using the male or female condom: results from a randomized controlled trial. AIDS 1998; 12:1851-1859.
9. Artz L, Macaluso M, Brill I, Kelaghan J, Austin H, Fleenor M, et al. Effectiveness of an intervention promoting the female condom to patients at sexually transmitted disease clinics. Am J Public Health 2000; 90:237-244.
10. Choi KH, Gregorich SE, Anderson K, Grinstead O, Gomez CA. Patterns and predictors of female condom use among ethnically diverse women attending family planning clinics. Sex Transm Dis 2003; 30:91-98.
11. Barbosa RM, Berqu E, Kalckmann S. Acceptability of the Female Condom in Different Social Contexts: Final Research Report. 1st edn. Brasilia: Ministry of Health, Secretariat for Health Policies, National STD/AIDS Coordinating Office; 1999.
12. Welsh MJ, Feldblum PJ, Kuyoh MA, Mwarogo P, Kungu D. Condom use during a community intervention trial in Kenya. Int J STD AIDS 2001; 12:469-474.
13. Schwartlander B, Stover J, Walker N, Bollinger L, Gutierrez JP, McGreevey W, et al. AIDS Resource needs for HIV/AIDS. Science 2001; 292:2434-2436.
14. Marseille E, Kahn JG, Billinghurst K, Saba J. Cost-effectiveness of the female condom in preventing HIV and STDs in commercial sex workers in rural South Africa. Soc Sci Med 2001; 52:135-148.
15. Beksinska M, Smit J, Mabude Z, Vijayakumar G, Joanis C. Performance of the Reality polyurethane female condom and a synthetic latex prototype: a randomized crossover trial among South African women. Contraception 2006; 73:386-393.
16. Smit J, Beksinska M, Vijayakumar G, Mabude Z. Short-term acceptability of the Reality polyurethane female condom and a synthetic latex prototype: a randomized crossover trial among South African women. Contraception 2006; 73:394-398.
17. Ministry of Health, Brazil. MonitorAIDS: The National STD/AIDS Program Monitoring System, version 2.1. Brasilia: Ministry of Health; 2004.
18. Human Sciences Research Council. Nelson Mandela HSRC Study of HIV/AIDS. Cape Town: Human Science Research Council; 2002.
19. IBOPE Group. Use, Purchase Pattern, and Access of Male Condoms in the Public Health System. [Private research conducted for the evaluation unit of the Network Access Point (NAP) do Brasil.] Brasilia: IBOPE; 2003.
20. Myer L, Mathews C, Little F. Condom gap in Africa is wider than study suggests. Br Med J 2001; 323:937.
21. Chequer P. Access to treatment and prevention: Brazil and beyond. Third International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, July 2005 [Monday plenary].
22. Geffen N, Nattrass N, Raubenheimer C. Centre for Social Science Research Working Paper No. 28: The Cost of HIV Prevention and Treatment Interventions in South Africa. Cape Town: University of Cape Town; 2003.
23. US Census Bureau. International Data Base, April 2005 version. Washington, DC: US Census Bureau; 2005.Available at http://www.census.gov/cgi- bin/ipc/idbsum.pl?cty=SF; 2005.
24. Weinstein M, Graham J, Siegel J, Fineberg H. Cost-effectiveness Analysis of AIDS Prevention Programs: Concepts, Complications and Illustrations. Washington, DC: National Academies Press; 1989.
25. Rehle TM, Saidel TJ, Hassig SE, Bouey PD, Gaillard EM, Sokal DC. AVERT: a user-friendly model to estimate the impact of HIV/sexually transmitted disease prevention interventions on HIV transmission. AIDS 1998; 12 (Suppl 2):S27-S35.
26. Cowan FM, French RS, Mayaud P, Gopal R, Robinson NJ, de Oliveira SA, et al. Seroepidemiological study of herpes simplex virus types 1 and 2 in Brazil, Estonia, India, Morocco, and Sri Lanka. Sex Transm Infect 2003; 79:286-290.
27. Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342:844-850.
28. Wilkinson D, Connolly AM, Harrison A, Lurie M, Karim SS. Sexually transmitted disease syndromes in rural South Africa Results from health facility surveillance. Sex Transm Dis 1998; 25:20-23.
29. Department of Health, Republic of South Africa. South Africa Demographic and Health Survey 1998. Washington, DC: Macro International; 1998. http://www.measuredhs.com/pubs/pdftoc.cfm?ID=360&PgName=country.cfm0ctry_id= 55.
30. Korenromp EL, Bakker R, de Vlas SJ, Robinson NJ, Hayes R, Habbema JD. Can behavior change explain increases in the proportion of genital ulcers attributable to herpes in sub-Saharan Africa? A simulation modeling study. Sex Transm Dis 2002; 29:228-238.
31. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS1265 trial. PLoS Med 2005; 2:e298.
32. Adam T, Lim SS, Mehta S, Bhutta ZA, Fogstad H, Mathai M, et al. Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries. Br Med J 2005; 331:1107.
33. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahe C, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005; 353:2158-2168.
34. Harris GT, Olukoga IA. A cost benefit analysis of an enhanced seat belt enforcement program in South Africa. Inj Prev 2005; 11:102-105.
35. Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al. (eds.). Disease Control Priorities in Developing Countries, 2nd edn. New York: Oxford University Press; 2006.
36. Laxminarayan R, Mills AJ, Breman JG, Measham AR, Alleyne G, Claeson M, et al. Advancement of global health: key messages from the Disease Control Priorities Project. Lancet 2006; 367:1193-1208.
37. Boily MC, Lowndes C, Alary M. The impact of HIV epidemic phases on the effectiveness of core group interventions: insights from mathematical models. Sex Transm Infect 2002; 78 (Suppl 1):i78-i90.
38. Rottingen JA, Garnett GP. The epidemiological and control implications of HIV transmission probabilities within partnerships. Sex Transm Dis 2002; 29:818-827.
39. Baggaley RF, Ferguson NM, Garnett GP. The epidemiologic impact of antiretroviral use predicted by mathematical models: a review. Emerg Themes Epidemiol 2005; 2:9.
40. World Health Organization. WHO Information Update: Considerations Regarding Reuse of the Female Condom. Geneva: World Health Organization; 2002. http://www.who.int/reproductive-health/stis/docs/reuse_FC2.pdf.